Karyopharm Therapeutics (KPTI) Change in Account Payables (2012 - 2025)

Karyopharm Therapeutics (KPTI) has 14 years of Change in Account Payables data on file, last reported at -$1.4 million in Q4 2025.

• Quarterly Change in Account Payables fell 105.47% year-over-year to -$1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.1 million (down 155.65% YoY) and the FY2025 annual result came in at -$1.1 million, down 155.65% from the prior year.
• Change in Account Payables declined to -$1.4 million in Q4 2025, from $2.8 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.3 million in Q1 2023 to a low of -$6.8 million in Q2 2023.
• A 5-year average of -$22350.0 and a median of -$703500.0 in 2021 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2021 — Change in Account Payables plunged 480.73% — and 2024, when it soared 322.17%.
• Tracing KPTI's Change in Account Payables over 5 years: stood at $722000.0 in 2021, then jumped by 171.47% to $2.0 million in 2022, then increased by 11.22% to $2.2 million in 2023, then sank by 131.01% to -$676000.0 in 2024, then tumbled by 105.47% to -$1.4 million in 2025.
• The last three Change in Account Payables figures came in at -$1.4 million (Q4 2025), $2.8 million (Q3 2025), and -$3.3 million (Q2 2025), per Business Quant data.